Dr. Reddy's Laboratories ↗

Part of Dr. Reddy's Laboratories.

1984 📍 Hyderabad, Telangana, India Active NSE DRREDDY NYSE RDY CIN L85195TG1984PLC004507 Pharmaceuticals & Healthcare

Search companies

Key Metrics of Dr. Reddy's Laboratories

Revenue₹20,533 Cr▼ 11.2% YoYFY 2025-26

EBITDA₹5,607 Cr▼ 33.1% YoY

Net profit₹3,220 Cr▼ 39.8% YoY

Net worth₹31,366 Cr▲ 8.7% YoY

Market cap$11.0BRDY · $13.23

Competitors10identified

About Dr. Reddy's Laboratories

Part of Dr. Reddy's Laboratories.

Sectors

Pharmaceuticals & HealthcareFormulations & Contract ManufacturingLarge Pharma CompaniesState-wise Pharma Manufacturers

Company details

Website: drreddys.com
Founded: 1984
Registered office: 8-2-337 Road No 3 Banjara Hills, Hyderabad, In-ts, 500034
Listed: NYSE: RDY
Listed: NSE: DRREDDY · ₹1,310.90

Operational Areas of Dr. Reddy's Laboratories

Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing

Pharmaceuticals & Healthcare›Large Pharma Companies

Pharmaceuticals & Healthcare›State-wise Pharma Manufacturers

Company summary

Entity details

CINL85195TG1984PLC004507

LEI code335800OVDPY3DVZR2798

State codeTG

PIN code500034

Current legal nameDR. REDDY'S LABORATORIES

Classification—

Listing statusListed (NSE: DRREDDY)

Registration no.004507

Company age42 years, 9 months

PAN—

CountryIndia

CityHyderabad

StateTelangana

Current statusActive

Date of incorporation01 Jan 1984

Registrar of companies—

Authorised capital—

Paid-up capital—

Employee count—

Compliance

Last AGM date—

Last balance sheet—

Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026

Industry classification

NIC code85195

Description of main activityHealth and social work

Description of business activityHealth and social work

SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing

US market & SEC filings

RDY · NYSE · SEC CIK 0001135951

Last price · 25 Oct 2026 $13.23 +0.30%

Market cap$11.0B

P/E8.7On FY 2020 diluted EPS

Volume3,983,312

SectorHealth CareBiotechnology: Pharmaceutical Preparations

Country · IPOIndia

RDY share price

Premium

Annual results (SEC EDGAR)

Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed

AOC-4 for FY 2025-2630 Oct 2026 Statutory due date · 4 days left

MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 34 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26

Indicative long-term—

Indicative short-term—

Score—

LiquidityAdequate

DirectionStable

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

Default	No default on record
Issuer cooperation	Cooperating
Credit enhancement	None – standalone rating
Information on file	56% · missing: Capex / investment plans, Lender details, Auditor details, Recent rating review (last 15 months)

Indicative assessment from public data using the published methodology factors; not a credit rating.

Registered office and contact

Registered office8-2-337 ROAD NO 3 BANJARA HILLS, HYDERABAD, IN-TS, 500034

GSTIN—

Email—

Websitehttp://www.drreddys.com

Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of Dr. Reddy's Laboratories

Competitors10identified

Locations2most in India

Top competitors by location

Company	Description	Domain	Founded	Location
Aurobindo Pharma	Part of Aurobindo Pharma.	aurobindo.com	1986	Hyderabad, India
Cipla	Part of Cipla.	cipla.com	1935	Mumbai, India
Lupin Ltd.	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	lupin.com	1968	India
Glenmark Pharmaceuticals	Part of Glenmark Pharmaceuticals.	glenmarkpharma.com	1977	Mumbai, India
Biocon	Part of Biocon.	biocon.com	1978	Bangalore, India
ALKEM LABORATORIES LIMITED	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	alkemlabs.com	1973	Mumbai, Maharashtra, India
Torrent Pharmaceuticals	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	torrentpharma.com	1959	Ahmedabad, India
Thomas Cook India	Part of Thomas Cook Group.	thomascook.in	1978	Mumbai, India
Divi's Laboratories	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	divislabs.com	1990	Hyderabad, India
Ipca Laboratories	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	ipcalabs.com	1949	Mumbai, India

Similar companies

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Group companies

Part of Dr. Reddy's Laboratories

BetapharmPharmaceuticals & Healthcare

Dr Reddy's Laboratories (United Kingdom)Pharmaceuticals & Healthcare

Dr. Reddy's LaboratoriesPharmaceuticals & Healthcare

Business activities and related parties

pharmaceutical industry

Filings

No filings on record yet.